U.S. markets open in 4 hours 59 minutes

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.88+2.24 (+7.56%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close29.64
Bid30.15 x 800
Ask0.00 x 1000
Day's Range29.18 - 32.83
52 Week Range12.00 - 75.00
Avg. Volume1,185,007
Market Cap4.061B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-14.64
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak

    Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak

    (Bloomberg) -- Vir Biotechnology Inc.’s stock has lost some of its luster after quadrupling earlier this year as competition heats up for Covid-19 antibody therapies. Yet its chief executive officer is looking ahead to the next viral scourge.With two well-heeled competitors ahead of it, Vir has pared a February surge to a still impressive 115% leap this year. Eli Lilly & Co.’s antibody treatment received an emergency use authorization on Nov. 9 and Regeneron Pharmaceuticals Inc.’s therapy got its nod over the weekend. Vir’s medicine is unique because it targets a variety of coronaviruses, CEO George Scangos said.It “has the potential not only to be effective against Covid-19, but it has a reasonable chance of also being effective against the next coronavirus outbreak,” Scangos said in an interview. An interim look at late-stage data for VIR-7831 is expected in January.Regeneron has touted its two-antibody cocktail as being better than single-antibody treatments like those from Lilly or Vir. Yet Scangos, a former Biogen Inc. chieftain, said that while Lilly and Regeneron’s medicines block the ability of the virus to infect cells, the virus could evade these antibodies by mutating.‘Babe Ruth’“Would you rather have two random baseball players or Babe Ruth?,” he said. “It’s not just the number but the quality and the characteristics of the antibody.”Vir’s antibody was developed not from a Covid-19 patient but from one who’d recovered from severe acute respiratory syndrome, or SARS, which is also caused by a coronavirus. The company chose an antibody that also works against Covid-19 and Scangos postulates that it responds to something in the SARS and Covid viruses that hasn’t changed over years of viral evolution.He also sees potential advantage for Vir’s antibody in its engagement of part of the immune system where Lilly and Regeneron’s molecules have had less potent activity.Baird’s Madhu Kumar, the only analyst with a sell-equivalent rating on Vir, is skeptical. He said this particular component of Lilly and Regeneron’s antibodies may be what led to some safety signals and “could trigger inflammatory cascades that could be detrimental to patients.” This particularly concerns hospitalized patients, which Vir is still studying, Kumar told Bloomberg.Email requests for comment to Lilly and Regeneron weren’t returned.Much of Kumar’s skepticism is tied to Vir’s valuation. Even after the stock pulled way back from a Feb. 27 record, it’s still has more than doubled this year. He’s also wary of the market for antibodies in general because successful vaccine results from Pfizer Inc. and partner BioNTech SE as well as Moderna Inc. have blunted its longer term “tail value.”Outside of Covid-19, Kumar has a positive view on Vir. “There’s a real company behind this,” he said, calling out Vir’s hepatitis B RNAi platform. Vir’s stock slipped as much as 3.2% in early Tuesday trading.Others on Wall Street take a more optimistic view with five analysts deeming it a buy, and one with a hold rating. The average analyst price target of $55 suggests the Street expects shares may almost double over the next 12 months.GlaxoSmithKline Plc is also a believer and has invested $250 million in San Francisco-based Vir. The duo are in a deal to pursue not only Covid-19 but future coronaviruses using CRISPR screening technology and artificial intelligence to find new compounds.(Updates to add shares in eleventh paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Analysts Have Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Estimates By 20%
    Simply Wall St.

    Analysts Have Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Estimates By 20%

    The analysts covering Vir Biotechnology, Inc. (NASDAQ:VIR) delivered a dose of negativity to shareholders today, by...

  • Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
    Simply Wall St.

    Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

    As you might know, Vir Biotechnology, Inc. (NASDAQ:VIR) last week released its latest third-quarter, and things did...